FindTrial
Sign In

T-cell Receptor-engineered T-cells

BIOLOGICAL2 trials

Sponsors

Fred Hutchinson Cancer Center

Conditions

Metastatic Malignant Solid NeoplasmProstate CarcinomaProstate Small Cell Neuroendocrine CarcinomaStage III Prostate Cancer AJCC v8Stage IV Prostate Cancer AJCC v8

Phase 1

Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations
RecruitingNCT06043713
Fred Hutchinson Cancer CenterMetastatic Malignant Solid Neoplasm
Start: 2023-12-15End: 2028-01-01Target: 24Updated: 2026-07-06
Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer
WithdrawnNCT06094842
Fred Hutchinson Cancer CenterProstate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage III Prostate Cancer AJCC v8 +1
Start: 2025-04-15End: 2028-03-15Updated: 2025-04-01

Related Papers

Phase I study of autologous CD8+ and CD4+ transgenic T cells expressing high-affinity KRAS G12V mutation-specific T cell receptors (FH-A11KRASG12V-TCR) in patients with metastatic pancreatic, colorectal, and non-small cell lung cancers with KRAS G12V mutations.
Journal of Clinical Oncology2025-01-27
Abstract CT082: Phase I study of autologous CD8+ and CD4+ transgenic T cells expressing high-affinity KRAS G12V mutation-specific T cell receptors (FH-A11KRASG12V-TCR) in patients with metastatic pancreatic, colorectal and non-small cell lung cancers with KRAS G12V mutations
Cancer Research2024-04-052 citations